ReShape Historical Balance Sheet

RSLS Stock

USD 0.44 0.03 6.38%

Trend analysis of ReShape Lifesciences balance sheet accounts such as Liabilities And Stockholders Equity of 11.6 M, Other Stockholder Equity of 775.6 M, Total Liabilities of 4.4 M or Short Long Term Debt Total of 224 K provides information on ReShape Lifesciences' total assets, liabilities, and equity, which is the actual value of ReShape Lifesciences to its prevalent stockholders. By breaking down trends over time using ReShape Lifesciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ReShape Lifesciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ReShape Lifesciences is a good buy for the upcoming year.

ReShape Lifesciences Inventory

4.52 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

About ReShape Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ReShape Lifesciences at a specified time, usually calculated after every quarter, six months, or one year. ReShape Lifesciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ReShape Lifesciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ReShape currently owns. An asset can also be divided into two categories, current and non-current.

ReShape Lifesciences Balance Sheet Chart

At this time, ReShape Lifesciences' Inventory is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 7.3 M in 2025.

Total Assets Other Assets Common Stock Shares Outstanding Other Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of ReShape Lifesciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ReShape Lifesciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from ReShape Lifesciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Inventory is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 7.3 M in 2025.

	2022	2023	2024	2025 (projected)
Total Liabilities	7.5M	4M	4.6M	4.4M
Other Stockholder Equity	627.9M	642.3M	738.6M	775.6M

Total Liab Other Stockholder Equity

ReShape Lifesciences balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt
Total Assets		0.97	-0.1	0.73	-0.01	0.11	0.58	0.11	-0.34	0.17	0.29	-0.31	0.32	0.23	0.92	0.39	-0.21	0.23	0.22	0.14	0.46	0.07	0.19	-0.29	0.29	0.25
Total Stockholder Equity	0.97		-0.1	0.8	-0.08	0.13	0.38	-0.03	-0.45	0.02	0.26	-0.32	0.25	0.23	0.9	0.43	-0.22	0.22	0.17	0.11	0.35	0.04	0.17	-0.22	0.28	0.21
Retained Earnings	-0.1	-0.1		0.09	0.39	-0.96	-0.04	0.43	-0.04	-0.35	-0.19	-0.23	-0.7	0.5	-0.14	0.28	-0.54	0.5	-0.76	0.53	0.46	0.0	-0.34	0.51	0.24	0.31
Other Assets	0.73	0.8	0.09		-0.13	-0.03	0.13	-0.2	-0.51	-0.36	-0.08	-0.08	-0.1	0.01	0.78	0.3	-0.38	0.01	-0.15	0.17	0.44	-0.13	-0.12	-0.05	-0.01	0.02
Common Stock Shares Outstanding	-0.01	-0.08	0.39	-0.13		-0.35	0.23	0.33	0.32	-0.11	-0.01	-0.57	-0.44	0.72	-0.29	0.19	-0.07	0.71	-0.39	0.64	0.33	-0.14	-0.06	-0.17	0.66	0.23
Other Stockholder Equity	0.11	0.13	-0.96	-0.03	-0.35		-0.03	-0.45	-0.03	0.29	0.1	0.21	0.63	-0.48	0.14	-0.32	0.55	-0.48	0.68	-0.51	-0.48	-0.07	0.27	-0.47	-0.19	-0.32
Total Liab	0.58	0.38	-0.04	0.13	0.23	-0.03		0.55	0.25	0.62	0.27	-0.09	0.38	0.14	0.51	0.06	-0.09	0.14	0.29	0.2	0.61	0.14	0.17	-0.39	0.15	0.29
Short Long Term Debt Total	0.11	-0.03	0.43	-0.2	0.33	-0.45	0.55		-0.12	0.32	-0.07	0.11	-0.12	0.22	0.12	-0.03	0.03	0.21	-0.2	0.22	0.57	-0.03	-0.19	0.25	0.07	0.7
Other Current Liab	-0.34	-0.45	-0.04	-0.51	0.32	-0.03	0.25	-0.12		0.42	0.44	-0.32	0.19	0.23	-0.5	-0.19	0.14	0.23	0.24	0.14	-0.09	0.07	0.47	-0.21	0.3	-0.5
Total Current Liabilities	0.17	0.02	-0.35	-0.36	-0.11	0.29	0.62	0.32	0.42		0.4	0.01	0.6	-0.03	0.1	-0.32	0.39	-0.02	0.59	-0.31	-0.11	0.1	0.42	-0.24	0.12	-0.02
Property Plant And Equipment Net	0.29	0.26	-0.19	-0.08	-0.01	0.1	0.27	-0.07	0.44	0.4		-0.49	0.53	0.38	0.13	0.21	0.39	0.37	0.52	-0.1	0.06	0.0	0.96	0.05	0.48	-0.37
Net Debt	-0.31	-0.32	-0.23	-0.08	-0.57	0.21	-0.09	0.11	-0.32	0.01	-0.49		0.21	-0.92	0.07	-0.51	0.09	-0.92	0.2	-0.5	0.02	0.06	-0.41	0.22	-0.95	0.04
Accounts Payable	0.32	0.25	-0.7	-0.1	-0.44	0.63	0.38	-0.12	0.19	0.6	0.53	0.21		-0.39	0.38	-0.21	0.39	-0.39	0.96	-0.57	-0.11	0.32	0.53	-0.21	-0.19	-0.31
Cash	0.23	0.23	0.5	0.01	0.72	-0.48	0.14	0.22	0.23	-0.03	0.38	-0.92	-0.39		-0.12	0.5	-0.12	1.0	-0.38	0.61	0.17	-0.11	0.27	-0.02	0.94	0.19
Non Current Assets Total	0.92	0.9	-0.14	0.78	-0.29	0.14	0.51	0.12	-0.5	0.1	0.13	0.07	0.38	-0.12		0.22	-0.23	-0.12	0.27	-0.05	0.51	0.09	0.04	-0.13	-0.09	0.24
Non Currrent Assets Other	0.39	0.43	0.28	0.3	0.19	-0.32	0.06	-0.03	-0.19	-0.32	0.21	-0.51	-0.21	0.5	0.22		-0.47	0.48	-0.33	0.43	0.16	0.39	0.07	-0.28	0.4	0.31
Long Term Debt	-0.21	-0.22	-0.54	-0.38	-0.07	0.55	-0.09	0.03	0.14	0.39	0.39	0.09	0.39	-0.12	-0.23	-0.47		-0.12	0.47	-0.52	-0.31	-0.37	0.53	0.19	0.06	-0.35
Cash And Short Term Investments	0.23	0.22	0.5	0.01	0.71	-0.48	0.14	0.21	0.23	-0.02	0.37	-0.92	-0.39	1.0	-0.12	0.48	-0.12		-0.38	0.61	0.17	-0.11	0.26	-0.02	0.94	0.19
Net Receivables	0.22	0.17	-0.76	-0.15	-0.39	0.68	0.29	-0.2	0.24	0.59	0.52	0.2	0.96	-0.38	0.27	-0.33	0.47	-0.38		-0.57	-0.2	0.13	0.56	-0.2	-0.17	-0.39
Common Stock Total Equity	0.14	0.11	0.53	0.17	0.64	-0.51	0.2	0.22	0.14	-0.31	-0.1	-0.5	-0.57	0.61	-0.05	0.43	-0.52	0.61	-0.57		0.42	-0.22	-0.19	-0.21	0.46	0.37
Non Current Liabilities Total	0.46	0.35	0.46	0.44	0.33	-0.48	0.61	0.57	-0.09	-0.11	0.06	0.02	-0.11	0.17	0.51	0.16	-0.31	0.17	-0.2	0.42		-0.08	-0.07	0.17	0.01	0.33
Other Current Assets	0.07	0.04	0.0	-0.13	-0.14	-0.07	0.14	-0.03	0.07	0.1	0.0	0.06	0.32	-0.11	0.09	0.39	-0.37	-0.11	0.13	-0.22	-0.08		-0.1	-0.27	-0.14	0.14
Property Plant And Equipment Gross	0.19	0.17	-0.34	-0.12	-0.06	0.27	0.17	-0.19	0.47	0.42	0.96	-0.41	0.53	0.27	0.04	0.07	0.53	0.26	0.56	-0.19	-0.07	-0.1		0.02	0.43	-0.46
Preferred Stock Total Equity	-0.29	-0.22	0.51	-0.05	-0.17	-0.47	-0.39	0.25	-0.21	-0.24	0.05	0.22	-0.21	-0.02	-0.13	-0.28	0.19	-0.02	-0.2	-0.21	0.17	-0.27	0.02		-0.14	-0.1
Total Current Assets	0.29	0.28	0.24	-0.01	0.66	-0.19	0.15	0.07	0.3	0.12	0.48	-0.95	-0.19	0.94	-0.09	0.4	0.06	0.94	-0.17	0.46	0.01	-0.14	0.43	-0.14		0.04
Short Term Debt	0.25	0.21	0.31	0.02	0.23	-0.32	0.29	0.7	-0.5	-0.02	-0.37	0.04	-0.31	0.19	0.24	0.31	-0.35	0.19	-0.39	0.37	0.33	0.14	-0.46	-0.1	0.04

Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	37.1M	54.3M	11.1M	10.7M	12.3M	11.6M
Total Stockholder Equity	14.5M	46.1M	3.7M	6.7M	7.7M	7.3M
Retained Earnings	(514.8M)	(576.8M)	(624.2M)	(635.6M)	(572.0M)	(543.4M)
Other Assets	99K	46K	1.5M	102K	117.3K	111.4K
Common Stock Shares Outstanding	26.0K	3.8K	7.3K	102.7K	92.4K	128.9K
Liabilities And Stockholders Equity	37.1M	54.3M	11.1M	10.7M	12.3M	11.6M
Other Stockholder Equity	529.4M	622.4M	627.9M	642.3M	738.6M	775.6M
Total Liab	22.6M	8.2M	7.5M	4M	4.6M	4.4M
Short Long Term Debt Total	9.5M	279K	171K	262K	235.8K	224.0K
Other Current Liab	7.2M	3.2M	5.1M	1.9M	2.2M	3.3M
Total Current Liabilities	11.6M	7.3M	7.5M	3.8M	4.3M	6.0M
Property Plant And Equipment Net	1.0M	1.7M	869K	310K	279K	265.1K
Net Debt	(2.5M)	(22.5M)	(3.7M)	(4.2M)	(4.8M)	(5.1M)
Accounts Payable	3.7M	3.5M	1.9M	1.7M	1.9M	1.3M
Cash	3.0M	22.8M	3.9M	4.5M	4.0M	3.8M
Non Current Assets Total	28.1M	24.0M	1.2M	367K	422.1K	400.9K
Non Currrent Assets Other	99K	46K	1.5M	29K	33.4K	31.7K
Cash And Short Term Investments	3.0M	22.8M	3.9M	4.5M	4.0M	3.8M
Net Receivables	2.6M	2.8M	2.2M	1.7M	1.9M	997.2K
Non Current Liabilities Total	11.0M	855K	2.6M	223K	200.7K	190.7K
Other Current Assets	1.1M	1.4M	265K	437K	393.3K	373.6K
Property Plant And Equipment Gross	1.0M	1.7M	1.2M	400K	360K	618.1K
Total Current Assets	8.9M	30.3M	9.9M	10.3M	9.3M	16.2M
Accumulated Other Comprehensive Income	(8K)	(121K)	(92K)	(88K)	(79.2K)	(83.2K)
Short Term Debt	314K	558K	342K	111K	99.9K	94.9K
Common Stock	6K	18K	1K	23K	20.7K	19.7K
Property Plant Equipment	16K	584K	1.7M	869K	782.1K	565.6K
Other Liab	6.2M	4.7M	1.6M	855K	983.3K	934.1K
Current Deferred Revenue	202K	398K	549K	44K	50.6K	53.1K
Inventory	2.2M	3.0M	3.6M	3.7M	4.3M	4.5M
Net Tangible Assets	(4.6M)	(12.5M)	25.2M	3.4M	3.1M	4.0M
Intangible Assets	28.7M	27.0M	20.8M	260K	299K	284.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ReShape Historical Balance Sheet

ReShape Lifesciences Inventory

4.52 Million

About ReShape Balance Sheet Analysis

ReShape Lifesciences Balance Sheet Chart

Total Assets

Common Stock Shares Outstanding

ReShape Lifesciences balance sheet Correlations

ReShape Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ReShape Lifesciences balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for ReShape Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.97	Total Assets
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net
Net Receivables	+ 0.96	Accounts Payable
Total Current Assets	+ 0.94	Cash
Total Current Assets	+ 0.94	Cash And Short Term Investments

Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Cash	- 0.92	Net Debt
Net Receivables	- 0.76	Retained Earnings
Accounts Payable	- 0.7	Retained Earnings